Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma Academic Article Article uri icon


MeSH Major

  • Gastrointestinal Neoplasms
  • HIV Infections
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms


  • A phase-II trial of 4-demethoxydaunorubicin (4-DMDR) was performed in 21 patients with advanced renal cell carcinoma. The drug had demonstrated a broader spectrum of activity with less cardiotoxicity in preclinical evaluation than the parent compound daunorubicin. The starting dose was 12.5 mg/m2, with escalations to 15 and 17.5 mg/m2 in the absence of toxicity. Myelosuppression was the primary toxicity and cardiac toxicity was not seen in four patients who received four or more doses of DMDR. No responses were seen in 19 adequately treated patients, including 14 who had received no prior therapy.

publication date

  • January 1985



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/BF00552731

PubMed ID

  • 3855289

Additional Document Info

start page

  • 79

end page

  • 80


  • 14


  • 1